CAC
LEXX icon

Cowen and Company’s Lexaria Bioscience LEXX Stock Holding History

Cowen and Company’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-256,327
Closed -$320K – 701
2023
Q4 		$320K Buy
+256,327
New +$330K 0.02% 194

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cowen and Company's LEXX Position: Q1 2024 in Review

Cowen and Company sold out of Lexaria Bioscience (LEXX) in Q1 2024, closing a stake of 256,327 shares — an estimated $320K sold.

Cowen and Company first reported a position in LEXX in Q4 2023 and held it in 1 quarter. The position peaked at $320K in Q4 2023. 25 funds tracked by Wall St. Rank hold LEXX as of Q1 2024.

  • Cowen and Company reported no remaining Lexaria Bioscience position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 256,327 Lexaria Bioscience shares in Q1 2024, an estimated $320K.
  • Cowen and Company first reported a position in Lexaria Bioscience in Q4 2023 and held it in 1 quarter.
  • Cowen and Company's Lexaria Bioscience position peaked at $320K in Q4 2023.
  • 25 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.